Nothing is easy about developing treatments for rare diseases. Patient populations are small, research funding scarce and markets limited. Yet almost all therapies that do emerge will need some form of commercialisation if they are to make it through the regulatory process and into the clinic.
Becker s asked C-suite executives from hospitals and health systems across the U. S. to share their organization s areas of growth for the next few years.